Unlocking the Power of Live-Cell Kinetics in Degrader Development

In targeted protein degradation (TPD), timing is everything. Understanding not just whether a degrader works—but how fast, how thoroughly and how sustainably—can dramatically influence early discovery decisions. Dr. Kristin Riching (Promega) dove into the real-time world of degradation kinetics in the webinar: Degradation in Motion: How Live-Cell Kinetics Drive Degrader Optimization, sharing how dynamic data provides a clearer view of degrader performance than traditional endpoint assays.

Whether you’re exploring your first PROTAC or optimizing a molecular glue series, the expertise offered in Dr. Riching’s presentation gives you actionable insights that will help you connect kinetic data to better therapeutic design.

3D visualization of a protein structure within a live-cell environment, highlighting the interaction site relevant to targeted protein degradation, set against a dark cellular background to emphasize kinetic dynamics.
Continue reading “Unlocking the Power of Live-Cell Kinetics in Degrader Development”

How The OceanOmics Centre is Using the Maxwell RSC to Scale eDNA Biodiversity Monitoring

This blog is written by guest blogger Ben Rushton, Application Specialist/Territory Manager at Promega Australia.

When you’re monitoring marine biodiversity at scale, every drop of seawater tells a story. At Minderoo OceanOmics Centre at the University of Western Australia, scientists are uncovering that story through environmental DNA (eDNA)—and automation is helping them listen more clearly.

Laura Missen, a Scientific Officer at OceanOmics Centre, shares how automating their DNA extraction workflow with the Maxwell® RSC 48 system has transformed how they gather and interpret data from marine ecosystems.

(Image credit: Giacomo d’Orlando / Ronin_Lab)
Continue reading “How The OceanOmics Centre is Using the Maxwell RSC to Scale eDNA Biodiversity Monitoring”

How Thalidomide and Molecular Glues Are Redefining Drug Discovery

Targeted protein degradation (TPD) is a strategy used to selectively remove proteins from cells, rather than simply blocking their activity. Traditional small-molecule drugs work by binding to a protein and inhibiting its function, leaving the protein intact. In contrast, TPD harnesses the cell waste-disposal system—in particular, the ubiquitin-proteasome pathway—to tag the target protein for destruction. Once tagged, the protein is chopped up and recycled by the proteasome, eliminating it from the cell.

Perhaps the best known TPD approach uses PROTACs (proteolysis-targeting chimeras), which are bifunctional molecules: one end binds the protein of interest, and the other recruits an E3 ubiquitin ligase. By bringing the protein and ligase together, the PROTAC triggers ubiquitin tagging and subsequent degradation.

How NanoBRET works image.

Molecular glues achieve the same end result—selective protein destruction—in a different way. Instead of acting as a physical bridge between the protein and the E3 ligase, molecular glues bind to one protein (often the ligase) and subtly change its shape or surface properties, improving interaction with the target protein. This induced fit causes the target protein to be ubiquitinated without a large, two-part molecule like a PROTAC.

Continue reading “How Thalidomide and Molecular Glues Are Redefining Drug Discovery”

Exploring the Relationship Between IC50 and Kd in Pharmacology

This guest blog post is written by Tian Yang, Associate Product Manager at Promega.

In the realm of chemical probe development and drug discovery, understanding the interactions between drugs/compounds and their targets is crucial. Two frequently used metrics to characterize these interactions are IC50 and Kd, which guide researchers in evaluating the potential of compounds in effecting changes in target function. IC50 offers insights into a compound’s potency by quantifying its ability to inhibit a specific biological activity. Kd provides a measure of the affinity between a ligand and its receptor, reflecting how tightly a compound binds to its target (1). Together, these parameters are instrumental in the early stages of drug development, helping to identify promising candidates by assessing a compounds’s binding characteristics and its observed efficacy.

Continue reading “Exploring the Relationship Between IC50 and Kd in Pharmacology”

Why mRNA Transfection Is Transforming Transient Expression Workflows

Transfection is a core technique in molecular biology used to introduce foreign nucleic acids—such as DNA, RNA, or small RNAs like siRNA, shRNA, and miRNA—into eukaryotic cells. This enables researchers to manipulate gene expression and study cellular processes, disease mechanisms and therapeutic strategies (1).

Advances in transfection technology now support a range of nucleic acid types and cell models. Researchers can pursue transient or stable expression to achieve specific goals: knocking down transcripts, expressing proteins, or probing promoter activity in systems from immortalized lines to stem cells (1).

Continue reading “Why mRNA Transfection Is Transforming Transient Expression Workflows”

An Unexpected Culprit in Heart Disease? Meet Your Gut Microbes 

For decades, heart disease–particularly atherosclerosis, a condition characterized by the buildup of plaque in the artery walls–has remained the world’s top health challenge despite major medical advances. Cholesterol and high-fat diets have long shouldered the blame, but new research published in Nature uncovers an unexpected suspect: our gut microbes.  

Continue reading “An Unexpected Culprit in Heart Disease? Meet Your Gut Microbes “

ATP-Powered Proteins Beyond Kinases – and Why Helicases Are Stealing the Spotlight

This blog was written by guest author Michael Curtin, Senior Product Manager, Small Molecule Drug Discovery.

ATP is the universal energy currency of cells, and thousands of proteins outside the kinase family “spend” it to move cargo, remodel nucleic acids, pump ions, or fold proteins. These ATP-hydrolyzing enzymes—collectively known as ATPases—span functional classes including motor proteins, transporters, chaperones, chromatin remodelers, ligases, and, crucially for genome stability, helicases.

From DNA replication to RNA processing, helicases are essential players. DNA/RNA helicases such as MCM, XPB/XPD, WRN, and members of the DDX family sit alongside AAA+ unfoldases, ABC transporters, and V-ATPases—all drawing on ATP to power their molecular work.

Continue reading “ATP-Powered Proteins Beyond Kinases – and Why Helicases Are Stealing the Spotlight”

Matching Luciferase Reporter Assays to Your Experimental Goals

Luciferase reporter assays are highly versatile, but their true power comes when the reporter system you’ve selected is well aligned with your experimental objectives. Whether you’re tracking transcriptional changes or pathway activity, assessing miRNA/siRNA regulation, or using as a readout in CRISPR-based screens, choosing a reporter and detection assay format that fit your specific research goal is critical for meaningful, reproducible results.

You may have already read about how to choose a luciferase reporter assay, but now, we will walk through how to match luciferase reporter systems—reporter types, detection chemistries, and formats—to your specific experimental needs. While luciferases like NanoLuc have applications beyond gene expression, this blog focuses on genetic reporter applications and the workflows that support them.

Continue reading “Matching Luciferase Reporter Assays to Your Experimental Goals”

HiBiT-Based NanoBRET® Assay Sheds Light on GPCR–Ligand Binding in Live Cells

G-protein-coupled receptors (GPCRs) are among the most important drug targets in human biology, mediating signals across nearly every physiological system. But not all GPCRs are equally easy to study—especially those that interact with peptide ligands. These ligands tend to be flexible, fast-moving, and hard to trace in live cells by standard methods. Historically, radioligand binding assays have filled this gap, offering a way to measure peptide–receptor interactions with high sensitivity. However, these assays are typically performed using isolated membrane preparations or cells under non-physiological conditions, and they don’t allow for real-time or kinetic measurements.

Artistic Image of Hibit Tag

Continue reading “HiBiT-Based NanoBRET® Assay Sheds Light on GPCR–Ligand Binding in Live Cells”

How Computational Design Can Predict the Next Viral Variant—and Help Us Prepare

As SARS-CoV-2 continues to evolve, one lesson is painfully clear: immunity today may not guarantee protection tomorrow. Viruses are experts at mutating into countless variants to evade detection or neutralization by the immune system. In the race to keep up with this “immune escape”, researchers have largely focused on reactive strategies—testing vaccines against variants that already exist. But what if we could flip the script and anticipate where the virus is going next?

That’s precisely the aim of a new study published in Immunity. This study introduces EVE-Vax, a computational design platform that builds synthetic spike proteins capable of mimicking immune escape mutations—before they naturally arise.

Continue reading “How Computational Design Can Predict the Next Viral Variant—and Help Us Prepare”